

Protein engineering for designing new antivirals


Laboratory for NanoBiology

PI: Rahul Roy

Protein engineering: antivirals and diagnostics

Challenge and Motivation

- Proteins in isolation (outside the cell) do not function well since they are missing co-factors and specific interactions
- This is especially true for viral proteins since the viruses have evolved to usurp the host cell proteins as co-factors.
- Protein engineering allows us to identify the mechanisms by which co-factors assist the viral proteins which can serve as potent targets for antivirals.
- We have recently developed a new framework for developing super-helicases from RNA viruses like dengue and zika.^{1, 2}
- Super-helicases can enhance the diagnostics of viral RNA³ and are good antiviral targets.
- Can we employ the super-helicases to identify antivirals against viruses?




¹Patent application pending; ²Banerjee et al. 2023
³ Volloly and Roy Anal. Chem. 2022

Project plan

Goals of the project

Reverse engineer viral RNA helicases using functional protein design

- A. Generate rationally designed viral RNA helicases
- B. Evaluate their functional mechanism using single molecule force-fluorescence spectroscopy
- C. Develop new viral diagnostics assays with super-helicases
- D. Identify ways to inactivate them with
 - a) Allosteric inhibition
 - b) Inhibition of interaction partners




Methods and Outcomes


Methods

- Virus evolution experiments under immune selection pressure
- Single-cell virus sequencing
- High throughput and automated virus variant characterizations
- Modeling of virus evolution
- Design and development of RNA nanostructure virus mimics as vaccine candidates


Structural dynamics and network analysis with ML



Deep mutational scanning



Single molecule experiments to characterize super-helicases



Outcomes

- Immune selection pressure predicted virus evolution strategies
- New methods for understanding virus evolution
- Designer RNA nanostructure virus mimics as vaccine candidates

Anti-virals against RNA helicases

